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Clinical translation of tolerance-inducing cell therapies requires a novel approach focused
on innovative networks, patient involvement, and, foremost, a fundamental paradigm shift
in thinking from both Academia, and Industry and Regulatory Agencies.Tolerance-inducing
cell products differ essentially from conventional drugs. They are personalized and target
interactive immunological networks to shift the balance toward tolerance. The human cell
products are often absent or fundamentally different in animals. This creates important
limitations of pre-clinical animal testing for safety and efficacy of these products and calls
for novel translational approaches, which require the combined efforts of the different par-
ties involved. Dedicated international and multidisciplinary consortia that focus on clinical
translation are of utmost importance. They can help in informing and educating regulatory
policy makers on the unique requirements for these cell products, ranging from pre-
clinical studies in animals to in vitro human studies. In addition, they can promote reliable
immunomonitoring tools.The development of tolerance-inducing cell products requires not
only bench-to-bedside but also reverse translation, from bedside back to the bench.
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Tolerance-inducing cellular therapies hold great promise for the
treatment of patients with chronic inflammation, as seen in
autoimmune diseases, and for the prevention of graft rejection
and graft-versus-host-disease (GvHD) following transplantation
(1, 2). Such treatments possess the key for a true restoration of the
immune balance and thus may prevent or minimize the life-long
use of immunosuppressive drugs and therewith associated adverse
side-effects. Their potential is supported by a vast amount of data
from in vitro human assays and experimental models (3–7). The
first cautious steps to clinical translation have been undertaken
by phase I and II studies with both regulatory T-cells (Tregs) and
tolerogenic dendritic cells (tolDC) in GvHD, organ transplanta-
tion, type I diabetes, and RA (2, 8–11). It is becoming increasingly
clear, however, that the intrinsic nature of tolerance-inducing cel-
lular products leads to unique requirements for safe and efficient
clinical translation. Here, we highlight some of the most notable
hurdles in translation of tolerance-inducing cellular therapies and
define some prerequisites that may substantially move the field
forward.
HURDLES IN CLINICAL TRANSLATION
To improve human health using cellular therapies, basic scien-
tific discoveries must be translated into pre-clinical studies [e.g.,
in vitro or in vivo (animal) model systems] and subsequently be
applied in human subjects in clinical studies. This process entails
a number of essential and intricate steps, which require optimal
fine-tuning. These steps serve to demonstrate proof-of-concept
for the therapeutic potential of the product and to gain optimal
information on the safety of the product. Failures or hurdles at
any of these steps will substantially slow down the translation of
the tolerance-inducing cell therapies (Figure 1 and Table 1).
WRONG INCENTIVES
Publications in high impact journals enhance the career of young
academic scientist and their esteem and improve their chances for
subsequent funding. Currently, these journals have a preference
for highly innovative studies, which are by nature often funda-
mental. Studies in human subjects are less straightforward and
relatively seldom make it to the top journals in the field. Thus, the
current academic reward structure has created a wrong incen-
tive for researchers, namely, to keep their research focused on
what yields the highest chance of a next top publication and not
on what directly or indirectly might be beneficial for translation
into human application. This can be considered as a detrimental
development for the design of novel clinical therapies.
CONFUSED REGULATORS
Currently, regulatory bodies treat cellular therapy in a similar fash-
ion as conventional drugs. Unfamiliarity with tolerance-inducing
cell therapies is at the basis of this view and is readily explained by
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FIGURE 1 | Steps and hurdles in clinical translation of tolerance-inducing cellular therapies.
Table 1 | How to move forward.
Hurdles How to move forward
Wrong incentive: human studies are less attractive because
of academic reward structure
Educate journals, granting organizations, and academic evaluators by creating awareness
about the limitations of animal models and value of studies involving human materials
Promote long-term, supervised grant structure for collaborative research focused on
human translational studies
Confused regulators: cellular therapies are treated similarly
as conventional drug
Create awareness that cellular therapies need new evaluation tools
Men are not mice: problems cured in animals do not
necessarily translate to therapy for human beings
Create awareness about differences between human beings and mice
Educate about the limitations and added value of mice models
Use the human model: invest in monitoring of clinical studies
Scattered research by many different research groups Promote extensive international collaborative networking
Insufficient patient partnering Involve patients/patients’ organizations more closely in the development of cellular
therapies
the novelty of these therapies. All cell-based therapeutic products
(irrespective whether they aim to induce immunological tolerance
or immune activation) are essentially different from conventional
chemical drugs. Still, for efficacy and safety of cell products,
regulatory agencies mostly rely on the models used for testing
conventional drugs. This leads to the request for similar product
requirements in extensive animal studies on dosage, conventional
toxicology, and pharmacodynamics. Many of the characteristics
of chemical compounds (solubility, diffusion capacity, turnover
into toxic side products) that are tested in such studies, however,
do not apply to cells. Therefore, these studies are often of little
use for predicting efficacy or safety of a cellular product upon
infusion. These studies create additional costs, slow down clin-
ical translation, and hamper effective progression of cell-based
therapies.
MEN ARE NOT MICE
Up to today, much emphasis has been put on the use of experi-
mental animal models as a necessary step toward the clinic, not
in the least by regulatory bodies. The use of animal models to
learn about mechanisms of action, define therapeutic targets, and
design potential therapeutics is beyond doubt. Meta-analysis has
shown that only about a third of highly cited animal research is
translated at the level of human randomized trials (12). This is in
part due to the fact that studies on animals do not always predict
the effects of immunomodulatory therapies in human beings cor-
rectly. Specifically, for tolerance-inducing therapies, its use needs
redefining.
It is important to distinguish the value of animal models based
on the type of immunomodulatory therapy used, i.e., biologi-
cals versus cell-based products. Studies in mice have contributed
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to the success of biologicals, e.g., TNFα blocking therapies. Ini-
tial interesting observations that TNFα blockage diminished IL-1
production in in vitro human rheumatoid synovial cultures led to
extensive studies in mouse models for rheumatoid arthritis, which
have resulted into very successful treatment of rheumatoid arthri-
tis with TNFα blocking agents in human beings [as reviewed in
Ref. (13)]. Also studies in mice supported evidence that inhibitory
molecules like CTLA-4 are involved in immune control and facili-
tated the use of anti-CTLA-4 antibodies in clinical practice to treat
cancer (14).
Clear differences exist between biologicals and cell-based prod-
ucts. First, biologicals are generated in batches, while cell-based
products are personalized and often consist of modified cells of
individual patients. This obviously complicates animal testing of
the latter. Biologicals are also different to cell-based products
in terms of mechanism of action. Whereas biologicals initially
target one single molecule, cellular products target multiple effec-
tor molecules and cells that act in highly interactive networks
to shift the immunological balance toward immune activation
(anti-cancer therapy) or toward immune tolerance. This fact has
important consequences when realizing that the human immune
system differs more from rodent models than often is assumed
in genetic make-up and immunological maturity. A recent study
clearly underscored that genome-wide inflammatory responses in
some major diseases/disease models significantly differed between
human beings and mice (15). As a consequence, experimental
models – though useful in many other ways – mimic poorly
human disease. Also for biologicals, the different genetic make-
up of the target of the biological in animal models compared to
human beings has created a false sense of safety in the past. The
development of anti-CD40 ligand antibodies to prevent trans-
plant rejection and treat SLE was halted when the first studies in
human beings showed thrombo-embolic complications (16, 17).
Subsequent studies indicate that this is caused by the activation
of surface FcγRIIa on human platelets, an FcR variant not present
on mice platelets (18). Next to genetic differences, also dissimilar
maturation of the immune systems in human beings and caged
animals may play a role. Mice are mostly studied at young age
and are not continuously exposed to pathogens. Consequently,
they are more immunological naïve compared to adult patient
populations. This further limits the suitability of mouse models
as the crucial preparatory step for bringing immunotherapy to
the clinic; an experienced and environmentally educated immune
system will most certainly react differently to immune interven-
tions. Since cell-based products act on an interactive network of
immunological targets, described differences in genetic make-up
and immunological maturity make especially evaluation of cell-
based products in animal models difficult, and may even create
a false sense of safety of the product. Furthermore, inadvertently
the preferred choice of administration routes often differs in mice
versus men, again questioning if findings can be translated from
mouse studies to application in human beings.
The application of tolerance-inducing cellular therapy for
autoimmunity is different compared to cellular therapy for other
indications. While anti-cancer cellular therapy treats terminally
ill patients, without alternative treatment options, tolerance-
inducing cellular products target patients with chronic diseases,
which are not directly life threatening. Also, tolerance-inducing
cells theoretically could even become pro-inflammatory in the
pro-inflammatory environment of autoimmune inflammation.
This asks for additional safety precautions and additional forms of
experimental testing. Some human cell types, however, are non-
existent in animals or show great differences in molecular pheno-
type and function. For instance, human- and mouse-induced Treg
have different regulators of their transcription and show differ-
ent stability (19, 20). This may lead to wrong leads and clues for
development of novel therapies in human beings.
Interestingly enough, the absence of appropriate small ani-
mal models has not hampered the HIV research field in mak-
ing tremendous advances. On the contrary, it may even have
stimulated a more rapid translation from bench-to-bedside.
HOW TO MOVE FORWARD
We foresee several ways to speed up the translation of tolerance-
inducing cell therapies into the clinic, as discussed below.
CHANGE INCENTIVES
The changed environment requires a transformation in the
appraisal of science. Because of the limitations of animal studies
for the final translation toward human beings, academic evalu-
ators and journals need to re-evaluate the value of the complex
and often more messy studies in human beings. Likewise, as sin-
gle research groups cannot perform such extensive human studies,
granting organizations should give priority support to large inter-
national and multidisciplinary consortia to prevent overlap and to
accelerate the process.
EDUCATE REGULATORS
Therapeutic cells have different mechanisms of action and a dif-
ferent safety profile compared to conventional chemical drugs or
“biologicals”and thus need to fit different regulatory requirements.
Currently, awareness is slowly arising that such therapies require
new requirements and evaluative tools (21). It is imperative that
academia, industry, and regulators work together to adapt the reg-
ulatory policy to meet these requirements. Initiatives such as from
Burroughs Welcome Fund (BWF) (22), which funds academic
research on innovative approaches for assessing the safety and
efficacy of new therapies, and as a result, promotes regulatory pol-
icy decisions based on the state-of-the-art science, are a promising
start.
USE A MODEL AS A MODEL
It is clear that men are not mice. If we want to cure a human disease,
we should keep this as a primary focus when considering the use
of experimental models. Though seemingly obvious, it requires
a paradigm shift in thinking, not only from researchers but also
from journals and regulators. To date, major journals and regula-
tors almost always request validation in animal models as a golden
standard. We believe that for the development of cellular therapy
this is not the right approach. Even “humanized” mouse models
can only mimic the human system and never completely reflect a
human disease with its enormous heterogeneity and complexity
(23). Animal models should be used for what they are developed
for, namely, as model for mechanistic pathways and not as model
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for a specific disease. As such, they can be instrumental for specific
issues that cannot be addressed in human beings directly, like the
in vivo interaction of cellular products with other immune cells
and local tissues and effects thereof. Animal models may be specif-
ically valuable to evaluate issues as homing, longevity, and stability
of the tolerance-inducing cellular products. Still, definite proof for
these issues needs to be obtained in clinical trials in human beings.
Therefore, while being a valuable source for mechanistic data and
safety data on product stability, animal models should not be used
as a single decisive requirement for tolerance-inducing cellular
therapy development.
USE THE HUMANMODEL
Efforts should be made to obtain data from human studies. For
example, migration potential, dosing, and life-span of tolerance-
inducing cell therapies can be deduced from experiences with
cellular therapy in cancer. Sometimes, a case-report in human
beings can be as valuable and informative as a study in a mouse
model (24). Certainly, the first trial on tolerance-inducing cell
therapies will yield valuable information. Phase “0” studies using
very low dosage of the product may be specifically considered
to establish the stability of the tolerance-promoting capacity of
the cellular product. Finally, to establish clinical efficacy of novel
tolerance-inducing cell therapies, it is imperative to define reliable
surrogate outcome parameters that reflect effective immunother-
apy. This needs to arise from reverse translation, i.e., from bedside-
to-bench, and thus again through studies in human beings (25).
For that reason, we strongly advocate that development of cell-
specific immunomonitoring technology in human beings is fur-
ther advanced and promoted. Thus, clinical and animal model-
based observations ideally should complement each other and lead
to insights, which would not be possible by either one alone.
SCIENTIFIC COLLABORATION
The development of cellular therapies can only be realized through
extensive international collaborative networking. Experience and
data should be shared to prevent repetition, waste of funding, and
to reach consensus on difficult questions. This requires a different
mind-set from the general competitive nature of basic biomed-
ical research. Promising initiatives in this respect are the ONE
study, a unified approach evaluating cellular immunotherapy in
solid organ transplantation, the Immune Tolerance Network (ITN,
sponsored by NIAID), the recently initiated EU COST Action A
FACTT (Action to Focus and Accelerate tolerance-inducing cel-
lular therapies), and the development of broad platforms for
biological studies such as UCAN-U (Understanding Childhood
Arthritis Network) (26).
INVOLVE THE STAKEHOLDERS
Patients (and patient organizations) are the true stakeholders
of cellular therapy development. They should be more closely
involved in risk and benefit analysis of cellular therapies. There
are various examples of patient organizations as true catalysts for
novel development, for example, in the field of muscular dystrophy
(27). We propose that basic scientists, clinicians, regulators, indus-
try, and patients collaboratively develop guidelines for strategic
development of defined cellular therapies.
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